Certara (NASDAQ:CERT) Price Target Lowered to $16.00 at UBS Group

Certara (NASDAQ:CERT) had its price target decreased by UBS Group from $20.00 to $16.00 in a research report sent to investors on Wednesday morning, Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other equities analysts have also commented on the stock. Barclays cut their price target on shares of Certara from $18.00 to $16.00 and set an equal weight rating on the stock in a report on Friday, June 28th. JMP Securities reiterated a market perform rating on shares of Certara in a report on Wednesday, July 10th. Finally, KeyCorp cut their price target on shares of Certara from $23.00 to $20.00 and set an overweight rating on the stock in a report on Thursday, July 11th. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $18.83.

Certara Stock Performance

Shares of CERT traded up $0.11 during mid-day trading on Wednesday, hitting $13.14. 628,529 shares of the company’s stock were exchanged, compared to its average volume of 573,379. Certara has a 52 week low of $11.81 and a 52 week high of $19.87. The stock’s 50-day simple moving average is $15.10 and its 200-day simple moving average is $16.52. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -34.85, a price-to-earnings-growth ratio of 5.39 and a beta of 1.52. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. During the same period last year, the business earned $0.10 earnings per share. The business’s revenue was up 3.2% compared to the same quarter last year. On average, equities research analysts expect that Certara will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Certara

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pineridge Advisors LLC bought a new stake in Certara in the 4th quarter worth about $28,000. Global Retirement Partners LLC grew its position in Certara by 5,306.3% in the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock worth $31,000 after purchasing an additional 1,698 shares in the last quarter. Blue Trust Inc. bought a new stake in Certara in the 2nd quarter worth about $26,000. Innealta Capital LLC bought a new position in shares of Certara during the 2nd quarter valued at approximately $36,000. Finally, YHB Investment Advisors Inc. bought a new position in shares of Certara during the 1st quarter valued at approximately $47,000. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.